Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsContinuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis.Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model.Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesCombination therapy for treatment of infections with gram-negative bacteria.Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceTreatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.Antibiotics for the critically ill: more than just selecting appropriate initial therapy.Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaAerosolized antibiotics: do they add to the treatment of pneumonia?Simplifying the treatment of acute bacterial bone and joint infections in children.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Treatment option for sepsis in children in the era of antibiotic resistance.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patienSerum concentrations of amoxicillin in neonates during continuous intravenous infusion.Saving lives with optimal antimicrobial chemotherapy.Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
P2860
Q24199096-B3679067-CEEA-4924-91A9-51E82F4C11A9Q34490565-022ADFA6-E75B-4BC3-A172-9D257C89AEC7Q34570641-DB656B81-706A-4FD2-A80C-4D72173D3900Q34923002-F61F6FD7-8766-438E-868F-78C98777AF76Q35986250-1DD72A68-9D1C-41D7-9F3A-282B25BC0A02Q36156077-BA0CFEE3-BF79-4FBB-99A2-BB277CE5A6FEQ36161206-D8D0D3E1-FAAC-4A27-9F62-C5AF2D74A4B9Q36329228-EFFD33E9-431C-43D9-BF20-9A842B7C1BD3Q36517624-335E865E-4BAC-4668-BB52-BB6209BCF38AQ36902744-768B22E6-34B9-4C22-BBC2-E1BCC7BC12F5Q36998603-E93F874E-BF45-4732-BAAB-D003389F09E0Q37220711-EA9F9355-BB16-4CFD-95DE-74231BBCD273Q37271774-6EDE8CCA-6DE6-452C-9EDB-A7EE43D509DDQ37960562-F0E1AAAD-7B06-4692-8297-FDA8A4576A39Q38004063-0926FB31-A2A2-47AB-BBC9-B93C80914CACQ38246118-26CFC321-0218-4365-8905-31605E3BBBC8Q38313276-57406936-D2B0-4148-A9F2-C24D475681A6Q38705266-9CA9B95A-AA3F-4E58-9476-9FAB450B586FQ38896040-20059533-E593-4FAD-B861-6A2D2E84BB64Q39586044-378D80BC-066B-4C84-9DDC-9BE95D57F868Q39665401-3B9D83A9-CF9B-445B-9FF4-0B912FD3D7D2Q40206253-0377D309-B5BF-460D-8475-70897AECEAE8Q40470332-0A2925A1-5705-45F4-B2A7-CC22A0409CE3Q40730766-CB9FCEA9-0CC0-4C01-92D4-747A0276A21DQ44358114-0260650B-54FF-41BD-AE5B-C0283112CBB4Q47861094-4830086C-7274-4E37-8054-AF59D96D3B4AQ49056677-5F0338F5-F6E3-44C4-B47A-AD6EAF83ABC0
P2860
Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@ast
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@en
type
label
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@ast
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@en
prefLabel
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@ast
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@en
P2093
P2860
P31
P921
P356
P1476
Does prolonged β-lactam infusi ...... randomized, controlled trials.
@en
P2093
Kyle J Van Arendonk
Michael L Rinke
Nirupama Putcha
Pranita D Tamma
Yong D Suh
P2860
P2888
P356
10.1186/1471-2334-11-181
P5008
P577
2011-06-22T00:00:00Z
P5875
P6179
1017207082